BACKGROUND AND PURPOSE: The increased risk of stroke and thromboembolism in atrial fibrillation (AF) may be related to a prothrombotic or hypercoagulable state, with abnormalities of hemostasis and platelet activation. To investigate the role of platelets in AF and the influence of antithrombotic therapy, we developed and then applied a new assay to detect the absolute amount of P-selectin per platelet (pP-selectin) based on cell lysis. Thus, pP-selectin in AF patients was compared with that of healthy controls and also with plasma soluble P-selectin (sP-selectin) and beta-thromboglobulin as established indices of platelet activation. METHODSMDSAH: We studied 122 patients (mean [SD] age, 71 [9] years; 65 men) with chronic AF of >6 weeks' duration: 34 were not on antithrombotic therapy, 30 were taking aspirin (75 to 300 mg/d), and 58 were fully anticoagulated with warfarin. pP-selectin was compared with sP-selectin and plasma beta-thromboglobulin levels (enzyme-linked immunosorbent assay). Results were compared with those of 23 healthy controls (mean [SD] age, 74 [9] years; 7 men) in sinus rhythm. RESULTS: pP-selectin was significantly lower in AF patients on no antithrombotic therapy (P=0.03) than in healthy controls, but sP-selectin and beta-thromboglobulin levels were not significantly different and did not differ in patients taking aspirin or warfarin. However, pP-selectin was lower in patients with AF on aspirin than in those on warfarin (P<0.05). pP-selectin/sP-selectin correlated significantly in healthy controls (r=0.47, P=0.03) but inversely (r=-0.43, P=0.03) in AF patients on no antithrombotic therapy. CONCLUSIONS: Lower levels of pP-selectin may represent a depletion of pP-selectin after platelet activation in AF. Aspirin further decreases pP-selectin levels compared with warfarin. On the basis of the principle of platelet lysis, we demonstrate that it is possible to determine the amount of P-selectin per platelet, which may be regulated in the megakaryocyte through a cyclooxygenase-dependent pathway.
BACKGROUND AND PURPOSE: The increased risk of stroke and thromboembolism in atrial fibrillation (AF) may be related to a prothrombotic or hypercoagulable state, with abnormalities of hemostasis and platelet activation. To investigate the role of platelets in AF and the influence of antithrombotic therapy, we developed and then applied a new assay to detect the absolute amount of P-selectin per platelet (pP-selectin) based on cell lysis. Thus, pP-selectin in AFpatients was compared with that of healthy controls and also with plasma soluble P-selectin (sP-selectin) and beta-thromboglobulin as established indices of platelet activation. METHODSMDSAH: We studied 122 patients (mean [SD] age, 71 [9] years; 65 men) with chronic AF of >6 weeks' duration: 34 were not on antithrombotic therapy, 30 were taking aspirin (75 to 300 mg/d), and 58 were fully anticoagulated with warfarin. pP-selectin was compared with sP-selectin and plasma beta-thromboglobulin levels (enzyme-linked immunosorbent assay). Results were compared with those of 23 healthy controls (mean [SD] age, 74 [9] years; 7 men) in sinus rhythm. RESULTS: pP-selectin was significantly lower in AFpatients on no antithrombotic therapy (P=0.03) than in healthy controls, but sP-selectin and beta-thromboglobulin levels were not significantly different and did not differ in patients taking aspirin or warfarin. However, pP-selectin was lower in patients with AF on aspirin than in those on warfarin (P<0.05). pP-selectin/sP-selectin correlated significantly in healthy controls (r=0.47, P=0.03) but inversely (r=-0.43, P=0.03) in AFpatients on no antithrombotic therapy. CONCLUSIONS: Lower levels of pP-selectin may represent a depletion of pP-selectin after platelet activation in AF. Aspirin further decreases pP-selectin levels compared with warfarin. On the basis of the principle of platelet lysis, we demonstrate that it is possible to determine the amount of P-selectin per platelet, which may be regulated in the megakaryocyte through a cyclooxygenase-dependent pathway.
Authors: Mats W Johansson; Shih-Tsung Han; Kristin A Gunderson; William W Busse; Nizar N Jarjour; Deane F Mosher Journal: Am J Respir Crit Care Med Date: 2012-01-06 Impact factor: 21.405
Authors: Jeffrey I Zwicker; Benjamin L Schlechter; Jack D Stopa; Howard A Liebman; Anita Aggarwal; Maneka Puligandla; Thomas Caughey; Kenneth A Bauer; Nancy Kuemmerle; Ellice Wong; Ted Wun; Marilyn McLaughlin; Manuel Hidalgo; Donna Neuberg; Bruce Furie; Robert Flaumenhaft Journal: JCI Insight Date: 2019-02-21
Authors: Mats W Johansson; Brandon M Grill; Karina T Barretto; Molly C Favour; Hazel M Schira; Calvin M Swanson; Kristine E Lee; Ronald L Sorkness; Deane F Mosher; Loren C Denlinger; Nizar N Jarjour Journal: Int Arch Allergy Immunol Date: 2020-08-10 Impact factor: 2.749
Authors: Na Wu; Shifei Tong; Ying Xiang; Long Wu; Bin Xu; Yao Zhang; Xiangyu Ma; Yafei Li; Zhiyuan Song; Li Zhong Journal: PLoS One Date: 2015-04-17 Impact factor: 3.240
Authors: Alexander Weymann; Sadeq Ali-Hasan-Al-Saegh; Anton Sabashnikov; Aron-Frederik Popov; Seyed Jalil Mirhosseini; Tong Liu; Mohammadreza Lotfaliani; Michel Pompeu Barros de Oliveira Sá; William L L Baker; Senol Yavuz; Mohamed Zeriouh; Jae-Sik Jang; Hamidreza Dehghan; Lei Meng; Luca Testa; Fabrizio D'Ascenzo; Umberto Benedetto; Gary Tse; Luis Nombela-Franco; Pascal M Dohmen; Abhishek J Deshmukh; Cecilia Linde; Giuseppe Biondi-Zoccai; Gregg W Stone; Hugh Calkins; Integrated Meta-Analysis Of Cardiac Surgery And Cardiology-Group Imcsc-Group Journal: Med Sci Monit Basic Res Date: 2017-05-12